--- title: "ENDRA reports second quarter 2026 results and merger progress" url: "https://aibio.space/news/endra-reports-second-quarter-2026-results-merger-progress/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-17" section: "Mergers" tickers: "NASDAQ:NDRA, NASDAQ:ASPI" source: "https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/ea030215601ex99-1.htm" summary: "ENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quart" --- By the aibio.space news desk. Sources - [ENDRA Life Sciences Inc. 8-K (2026-08-17)](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/ea030215601ex99-1.htm) - [ENDRA Life Sciences Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/) [NDRA](https://aibio.space/companies/endra-life-sciences/) [ASPI](https://aibio.space/companies/asp-isotopes/) 2026-08-17 # ENDRA reports second quarter 2026 results and merger progress Tickers [NDRA](https://aibio.space/companies/endra-life-sciences/)[ASPI](https://aibio.space/companies/asp-isotopes/) ENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quarter of 2026. ## Key facts - **Companies**: ENDRA Life Sciences Inc. (NASDAQ: NDRA), ASP Isotopes Inc. (NASDAQ: ASPI) - **News type**: Mergers - **Primary source**: [ENDRA Life Sciences Inc. 8-K (2026-08-17)](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/ea030215601ex99-1.htm) *Midtown Manhattan and a downtown tower in haze. CC0, via rawpixel. The picture shows the field, not the companies named.* ENDRA Life Sciences Inc. (Nasdaq: [NDRA](https://aibio.space/companies/endra-life-sciences/)) reported financial results for the quarter ended June 30, 2026, in a press release dated August 17, 2026, furnished as Exhibit 99.1 to a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/ea030215601ex99-1.htm). The release also gives a business update on the company's merger agreement with ASP Isotopes Inc. (Nasdaq: [ASPI](https://aibio.space/companies/asp-isotopes/)), Noble Africa LLC and Renergen Limited. ENDRA describes itself as a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease. The company reported net income of approximately $160,000 for the second quarter of 2026, compared with a net loss of approximately $1.2 million in the second quarter of 2025. ## The proposed merger The merger agreement was signed on June 25, 2026. Under its terms, Noble Africa will merge with a wholly owned subsidiary of ENDRA, and Noble Africa will survive as a wholly owned subsidiary of ENDRA. Upon completion, ENDRA will be renamed Noble Africa Inc. The company says the transaction is intended to give investors exposure to Renergen's Virginia Gas Project in South Africa. Noble Africa also entered into subscription agreements with institutional and other investors, as well as ASP Isotopes, for a private placement expected to generate approximately $50 million in gross proceeds. That placement is expected to close at the same time as the merger. The release says closing is expected in the fourth quarter of 2026, subject to customary closing conditions, including applicable stockholder and regulatory approvals. Chairman and Chief Executive Officer Alexander Tokman said the transaction gives ENDRA stockholders an opportunity to participate in the potential growth of "a differentiated helium platform." He said the company is working with ASP Isotopes, Renergen and Noble Africa toward satisfying the conditions needed to complete the merger. ## Financing and spending ENDRA completed a $3.8 million private placement on May 28, 2026, which it described as strengthening its balance sheet while it pursued its strategic alternatives process. As of June 30, 2026, the $3.8 million of proceeds were classified as restricted cash under the terms of that financing. The release says research and development expenses decreased 39% and sales and marketing expenses decreased 92% compared with the second quarter of 2025. ## Second quarter results As of June 30, 2026, ENDRA had approximately $1.7 million in cash, $3.8 million in restricted cash and $1.9 million in its Digital Asset Treasury. Cash used in operations was approximately $0.9 million in the second quarter of 2026, compared with approximately $1.1 million in the same period of 2025. Total operating expenses were approximately $1.5 million, compared with approximately $1.3 million a year earlier. Operating expenses included approximately $542,000 of non-cash stock-based compensation, compared with approximately $89,000 in the second quarter of 2025. Other income was approximately $1.6 million, primarily reflecting realized and unrealized gains associated with the digital asset treasury. The company reported net income of approximately $160,000 for the quarter. ## Full-year context The company's XBRL data, from its annual report for 2025 filed March 31, 2026, show research and development expense of $1.8 million for 2025, compared with $3.2 million for 2024. The net loss was $7.0 million for 2025, compared with $11.5 million for 2024. Cash used in operations was $5.2 million in 2025, compared with $7.4 million in 2024. ## The risks ahead ENDRA still has to close the merger, which the release expects in the fourth quarter of 2026 subject to stockholder and regulatory approvals. Quarterly net income came mainly from other income tied to its digital asset treasury, while the company lost approximately $1.2 million in the year-earlier quarter and $7.0 million in all of 2025. The release lists risks including that the proposed financings are not completed, that a delay could affect ENDRA's cash resources, continued Nasdaq listing until closing, and securities class action litigation that could divert management's attention. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story NDRA ENDRA Life Sciences Inc. NASDAQ · United States Open the starter desk ASPI ASP Isotopes Inc. NASDAQ · Not recorded Open the starter desk ## More in Mergers Mergers ### [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/) Oct 27, 2026 Mergers ### [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/) Oct 26, 2026 Mergers ### [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/) Oct 26, 2026 --- Source page: https://aibio.space/news/endra-reports-second-quarter-2026-results-merger-progress/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ENDRA reports second quarter 2026 results and merger progress", 2026-08-17, https://aibio.space/news/endra-reports-second-quarter-2026-results-merger-progress/